Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 15:14:1237454.
doi: 10.3389/fphar.2023.1237454. eCollection 2023.

Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary healthcare in Catalonia

Maria Giner-Soriano #  1   2 , Dan Ouchi #  1   2 , Roser Vives  3   4 , Carles Vilaplana-Carnerero  1   2   5   6 , Andrea Molina  3   4 , Antoni Vallano  3   4   7 , Rosa Morros #  1   3   5   7
Affiliations

Effectiveness and safety of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary healthcare in Catalonia

Maria Giner-Soriano et al. Front Pharmacol. .

Abstract

Objectives: Our objective was to analyse effectiveness and safety of oral anticoagulants (OAC) for stroke prevention in non-valvular atrial fibrillation. Material and methods: Population-based cohort study including adults initiating oral anticoagulants, either direct oral anticoagulants (DOAC) or vitamin K antagonists (VKA), during 2011-2020. Data source: SIDIAP, capturing information from the electronic health records of Primary Health Care in Catalonia, Spain. Study outcomes: stroke, cerebral and gastrointestinal (GI) haemorrhage, assessed by patients' subgroups according to different clinical characteristics. Results: We included 90,773 patients. Male sex, older than 75, previous event, peripheral artery disease, deep vein thrombosis, or receiving antiplatelets, antidiabetics or proton pump inhibitors (PPI) was associated with higher stroke risk. For DOAC-treated, treatment switch increased stroke risk, while being adherent had a protective effect. Men, antidiabetic treatment or a previous event increased the risk of cerebral bleeding. Receiving direct oral anticoagulants had a protective effect in comparison to vitamin K antagonists. For DOAC-treated, treatment switch increased, and adherence decreased the bleeding risk. Men, people with chronic kidney disease or a previous event posed an increased risk of gastrointestinal bleeding, whereas receiving PPI had a protective effect. For DOAC-treated, switch was associated with a higher bleeding risk. Conclusion: Being men, a previous event and DOAC-switch posed a higher risk for all study outcomes. direct oral anticoagulants had a protective effect against cerebral bleeding in comparison to vitamin K antagonists. Adherence to direct oral anticoagulants resulted in lower risk of stroke and cerebral bleeding. We found no differences in the risk of stroke and gastrointestinal bleeding when we compared direct oral anticoagulants vs. vitamin K antagonists.

Keywords: adherence; atrial fibrillation; effectiveness; electronic health records; oral anticoagulants; primary healthcare; safety; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Exposure-based cohort entry Figure 1 depicts the time of variables’ assessment at cohort entry. *Earliest of: outcome of interest (stroke, cerebral or gastrointestinal bleeding), death, disenrollment, end of study period. OAC: oral anticoagulants. AF: atrial fibrillation. PE: pulmonary embolism. DVT: deep vein thrombosis. Adapted from Schneeweiss et al., 2019; Schneeweiss et al., 2019).
FIGURE 2
FIGURE 2
Flow diagram of population included Flowchart of patients’ inclusion in the study. SIDIAP: Information System for the Development of Research in Primary Care. AF: atrial fibrillation. NVAF: non-valvular atrial fibrillation. OAC: oral anticoagulants. PE: pulmonary embolism. DVT: deep vein thrombosis.
FIGURE 3
FIGURE 3
Forest plot of the incidence rate ratios of stroke, cerebral and gastrointestinal haemorrhages in patients treated with oral anticoagulants Figure 3 depicts the adjusted Incidence Rate Ratios of stroke, cerebral and gastrointestinal haemorrhages in the group of patients treated with DOAC in comparison with VKA, and in those receiving DOAC according to dose adequacy, adherence, and treatment switch. DOAC: direct oral anticoagulants. VKA: vitamin K antagonists. MPR: medication possession ratio.
See this image and copyright information in PMC

References

    1. Abraham N. S., Noseworthy P. A., Yao X., Sangaralingham L. R., Shah N. D. (2017). Gastrointestinal safety of direct oral anticoagulants: A large population-based study. Gastroenterology 152, 1014–1022. 10.1053/j.gastro.2016.12.018 - DOI - PubMed
    1. Ahn H. J., Lee S. R., Choi E. K., Rhee T. M., Kwon S., Oh S., et al. (2022). Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis. Br. J. Clin. Pharmacol. 88, 4676–4687. 10.1111/BCP.15478 - DOI - PubMed
    1. Amin A., Marrs J. C. (2015). Direct oral anticoagulants for the management of thromboembolic disorders: The importance of adherence and persistence in achieving beneficial outcomes. Clin. Appl. Thrombosis/Hemostasis 27, 605–616. 10.1177/1076029615601492 - DOI - PubMed
    1. Anguita Sánchez M., Bertomeu Martínez V., Ruiz Ortiz M., Cequier Fillat Á., Roldán Rabadán I., Muñiz García J., et al. (2020). Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study. Rev. Esp. Cardiol. 73, 14–20. 10.1016/j.rec.2019.02.021 - DOI - PubMed
    1. Bang O. Y., On Y. K., Lee M. Y., Jang S. W., Han S., Han S., et al. (2020). The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis. PLoS One 15, e0242922. 10.1371/JOURNAL.PONE.0242922 - DOI - PMC - PubMed

LinkOut - more resources